IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).

医学 肿瘤科 内科学 肺癌
作者
Taofeek K. Owonikoko,Lauren A. Byers,Ying Cheng,Hidetoshi Hayashi,Luis Paz‐Ares,M. Pérol,Jennifer Turner,Meng Qian,Cecilio Roi Garcia,J. Godard,Charles M. Rudin
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): TPS8126-TPS8126 被引量:7
标识
DOI:10.1200/jco.2024.42.16_suppl.tps8126
摘要

TPS8126 Background: SCLC is an aggressive malignancy, and patients (pts) with extensive stage (ES)-SCLC have a relatively short median overall survival (OS), with limited treatment options beyond first-line (1L) therapy. B7 homolog 3 (B7-H3 [CD276]) is a transmembrane protein expressed in many solid tumors but with low/no expression in normal tissue. In SCLC, B7-H3 is highly expressed and associated with poor prognosis and lack of response to standard therapy. I-DXd is a B7-H3-directed antibody–drug conjugate comprising an anti-B7-H3 mAb linked to a topoisomerase I inhibitor payload (DXd) via a stable cleavable linker, designed to enhance selective tumor cell death and reduce systemic exposure. I-DXd demonstrated durable efficacy (objective response rate [ORR] 52.4%; median duration of response [DoR] 5.9 mo; median OS 12.2 mo) irrespective of B7-H3 status, with a manageable safety profile in 21 ES-SCLC pts with a median of 2 prior lines of therapy in a Phase 1/2 trial (NCT04145622). I-DXd is being investigated in an ongoing Phase 2 trial in pretreated ES-SCLC, IDeate-Lung01 (NCT05280470). We describe a Phase 3 trial comparing the efficacy and safety of I-DXd vs TPC in relapsed SCLC. Methods: IDeate-Lung02 (NCT06203210) is a global, multicenter, randomized, open-label, Phase 3 trial in adult pts with relapsed SCLC who have received 1 prior line of platinum-based therapy and have an ECOG PS of ≤1; pts with asymptomatic brain metastases are eligible. Pts are randomized 1:1 to receive I-DXd 12 mg/kg iv every 3 wks (n = 234) or TPC (n = 234; topotecan, amrubicin, or lurbinectedin). Randomization is stratified by chemotherapy-free interval after 1L therapy (< 90 vs ≥90 days); TPC (topotecan vs amrubicin vs lurbinectedin); prior treatment with PD-(L)1 (yes vs no); and presence/history of asymptomatic brain metastases (yes vs no). Study treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, death, loss to follow-up, or other reasons per protocol. Radiographic tumor assessments occur every 6 wks for 48 wks, then every 12 wks. Dual primary efficacy endpoints are ORR per RECIST v1.1 by blinded independent central review (BICR) and OS. Secondary efficacy endpoints are ORR per investigator; progression-free survival, DoR, disease control rate and time to response by BICR and investigator; and patient-reported outcomes. Safety endpoints include incidence of treatment-emergent adverse events (TEAEs), deaths, serious TEAEs, and TEAEs leading to dose modification or discontinuation. Immunogenicity of I-DXd and relationship between B7-H3 expression and clinical outcome are also secondary objectives. ORR will be analyzed using a Cochran-Mantel-Haenszel test at a 2-sided 1% alpha level, and OS will be analyzed using a log-rank test at a 2-sided 4% significance level, under a 2-look group sequential design. Clinical trial information: NCT06203210 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
学霸颖完成签到,获得积分20
刚刚
桐桐的应助被樊焕焕采纳,获得10
刚刚
斯文败类的应助被张智磊采纳,获得10
1秒前
极限001的应助被科研蚂蚁采纳,获得30
1秒前
2秒前
KK发布了新的文献求助10
2秒前
2秒前
zjc完成签到,获得积分10
2秒前
yfn完成签到,获得积分10
5秒前
5秒前
包容映安发布了新的文献求助10
6秒前
6秒前
阿狸完成签到,获得积分10
6秒前
w7完成签到 ,获得积分10
6秒前
隐形曼青的应助被hyfwkd采纳,获得30
6秒前
6秒前
7秒前
7秒前
7秒前
7秒前
PENGQIDU完成签到 ,获得积分10
7秒前
CaliU发布了新的文献求助10
7秒前
捏鱼发布了新的文献求助10
7秒前
荼蘼发布了新的文献求助10
7秒前
8秒前
8秒前
成_顺发布了新的文献求助10
8秒前
9秒前
无题发布了新的文献求助10
9秒前
9秒前
一条小鱼发布了新的文献求助10
10秒前
Abracadabra完成签到,获得积分10
10秒前
10秒前
Sheryl完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
zxdzaz完成签到 ,获得积分10
12秒前
如意的小鸭子完成签到 ,获得积分10
12秒前
zcx完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241